Literature DB >> 16815250

Retinopathy of prematurity: two distinct mechanisms that underlie zone 1 and zone 2 disease.

John T Flynn1, Tailoi Chan-Ling.   

Abstract

PURPOSE: In its most severe form, retinopathy of prematurity (ROP) is located in posterior retina and affects the smallest, most premature infants. We hypothesize that, depending on whether vasculogenesis (de novo formation of new vessels by transformation of vascular precursor cells (VPCs)) or angiogenesis (budding from existing vessels) is perturbed, it results in significant differences in clinical presentation and therapeutic outcome observed in zone 1 vs zone 2 ROP.
DESIGN: The study is a retrospective analysis of the difference in outcome between zones 1 and 2 ROP after cryotherapy and laser therapy.
METHODS: A review of the clinical presentation of zones 1 and 2 ROP that correlate this with the topography of formation of human retinal vasculature through vasculogenesis and angiogenesis.
RESULTS: Population data on susceptible infants, and outcome statistics of clinical trials are given. Digital images show a correlation between ROP in zone 1 with the region of the retina vascularized through vasculogenesis.
CONCLUSION: Zone 1 ROP is correlated with vessel development by vasculogenesis, relative insensitivity to laser/cryotherapy and poorer anatomic and visual outcomes. This suggests that, if the vasculogenic process is perturbed, it results in a distinct clinical presentation, poorer response to therapy, and poorer visual outcome. When the current international classification was developed, knowledge of the processes of human retinal vascular development was incomplete. The work presented here provides a framework for the development of a modification to incorporate these ideas without sacrifice of the essential elements of the international classification of ROP.

Entities:  

Mesh:

Year:  2006        PMID: 16815250     DOI: 10.1016/j.ajo.2006.02.018

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  31 in total

1.  Intravitreal bevacizumab in retinopathy of prematurity: an interventional case series.

Authors:  Ramak Roohipoor; Hamed Ghasemi; Fariba Ghassemi; Reza Karkhaneh; Mohammad Riazi-Esfahani; Mehdi Nili-Ahmadabadi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-04-15       Impact factor: 3.117

2.  Computer-aided diagnosis of retinopathy in retinal fundus images of preterm infants via quantification of vascular tortuosity.

Authors:  Faraz Oloumi; Rangaraj M Rangayyan; Anna L Ells
Journal:  J Med Imaging (Bellingham)       Date:  2016-12-15

3.  Role of hematological parameters in predicting retinopathy of prematurity (ROP) in preterm neonates.

Authors:  H S Niranjan; K R Bharath Kumar Reddy; Naveen Benakappa; Krishna Murthy; Shivananda Shivananda; Vishwanath Veeranna
Journal:  Indian J Pediatr       Date:  2013-02-23       Impact factor: 1.967

4.  Aqueous cytokine levels associated with severity of type 1 retinopathy of prematurity and treatment response to ranibizumab.

Authors:  Jiao Lyu; Qi Zhang; Haiying Jin; Yu Xu; Chunli Chen; Xunda Ji; Xiang Zhang; Yuqing Rao; Peiquan Zhao
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-06-09       Impact factor: 3.117

5.  Macular features from spectral-domain optical coherence tomography as an adjunct to indirect ophthalmoscopy in retinopathy of prematurity.

Authors:  Annie C Lee; Ramiro S Maldonado; Neeru Sarin; Rachelle V O'Connell; David K Wallace; Sharon F Freedman; Michael Cotten; Cynthia A Toth
Journal:  Retina       Date:  2011-09       Impact factor: 4.256

6.  The matricellular protein cysteine-rich protein 61 (CCN1/Cyr61) enhances physiological adaptation of retinal vessels and reduces pathological neovascularization associated with ischemic retinopathy.

Authors:  Adeel Hasan; Nataliya Pokeza; Lynn Shaw; Hyun-Seung Lee; Douglas Lazzaro; Hemabindu Chintala; Daniel Rosenbaum; Maria B Grant; Brahim Chaqour
Journal:  J Biol Chem       Date:  2011-01-06       Impact factor: 5.157

7.  Intraocular and systemic levels of vascular endothelial growth factor in advanced cases of retinopathy of prematurity.

Authors:  Raul Velez-Montoya; Carmen Clapp; Jose Carlos Rivera; Gerardo Garcia-Aguirre; Virgilio Morales-Cantón; Jans Fromow-Guerra; Jose Luis Guerrero-Naranjo; Hugo Quiroz-Mercado
Journal:  Clin Ophthalmol       Date:  2010-09-07

8.  Insights into advanced retinopathy of prematurity using handheld spectral domain optical coherence tomography imaging.

Authors:  Sai H Chavala; Sina Farsiu; Ramiro Maldonado; David K Wallace; Sharon F Freedman; Cynthia A Toth
Journal:  Ophthalmology       Date:  2009-09-18       Impact factor: 12.079

9.  Aggressive Posterior Retinopathy of Prematurity: Clinical and Quantitative Imaging Features in a Large North American Cohort.

Authors:  Kellyn N Bellsmith; James Brown; Sang Jin Kim; Isaac H Goldstein; Aaron Coyner; Susan Ostmo; Kishan Gupta; R V Paul Chan; Jayashree Kalpathy-Cramer; Michael F Chiang; J Peter Campbell
Journal:  Ophthalmology       Date:  2020-02-07       Impact factor: 12.079

10.  Combination of laser photocoagulation and intravitreal bevacizumab (Avastin) for aggressive zone I retinopathy of prematurity.

Authors:  Eun Jee Chung; Ji Hyun Kim; Hyun Seok Ahn; Hyoung Jun Koh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-10       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.